2004
Gefitinib — a novel targeted approach to treating cancer
Herbst RS, Fukuoka M, Baselga J. Gefitinib — a novel targeted approach to treating cancer. Nature Reviews Cancer 2004, 4: 956-965. PMID: 15573117, DOI: 10.1038/nrc1506.Peer-Reviewed Original Research
2003
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clinical Cancer Research 2003, 9: 5813-24. PMID: 14676101.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerEGFR-TK inhibitorsSystemic chemotherapyClinical trialsClinical developmentMetastatic non-small cell lung cancerTwo-drug combination regimenEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibSingle-agent activityRate of deathNew treatment approachesKinase inhibitor gefitinibEpidermal growth factor receptorGrowth factor receptorCombination regimenDisease progressionPlatinum agentsTreatment approachesSolid tumorsTumor growthInhibitor gefitinibTherapyCancerTargeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agents